NODAL MARGINAL ZONE LYMPHOMA
Clinical trials for NODAL MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NODAL MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for NODAL MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Matched conditions: NODAL MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…
Matched conditions: NODAL MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
Disease control Recruiting nowThis study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…
Matched conditions: NODAL MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Scientists dive into DNA of rare lymphoma to predict outcomes
Knowledge-focused Recruiting nowThis study looks at tumor samples from 300 people with nodal marginal zone lymphoma, a rare blood cancer. Researchers want to find genetic patterns that help predict how the disease will behave. The goal is to better understand the disease and improve future treatment decisions.
Matched conditions: NODAL MARGINAL ZONE LYMPHOMA
Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC